Biogen Analysts Lower Their Forecasts After Q4 Results

Benzinga

02-13

Biogen Inc (NASDAQ:BIIB) reported better-than-expected earnings for its fourth quarter on Wednesday.

The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.

Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.

Biogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.

Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.

Biogen shares fell 4.3% to close at $133.43 on Wednesday.

These analysts made changes to their price targets on Biogen following earnings announcement.

Canaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.
Truist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.
HC Wainwright & Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.

Considering buying BIIB stock? Here’s what analysts think:

Read This Next:

Top 3 Utilities Stocks That May Collapse In Q1

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2511240528"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2511240528\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2511240528?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2511240528","market":"hk","top_or_hot":-1,"title":"Biogen Analysts Lower Their Forecasts After Q4 Results","media":"Benzinga","content":"<html><body><p><strong>Biogen Inc</strong> (NASDAQ:BIIB) reported better-than-expected earnings for its fourth quarter on Wednesday.</p>\n<p>The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.</p>\n<p>Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.</p>\n<p>Biogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.</p>\n<p>Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.</p>\n<p>Biogen shares fell 4.3% to close at $133.43 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Biogen following earnings announcement.</p>\n<ul>\n<li>Canaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.</li>\n<li>Truist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.</li>\n<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.</li>\n</ul>\n<p><strong>Considering buying BIIB stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"569\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121.png 1135w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 3 Utilities Stocks That May Collapse In Q1</strong></li>\n</ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Analysts Lower Their Forecasts After Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Analysts Lower Their Forecasts After Q4 Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2025-02-13 22:03</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong>Biogen Inc</strong> (NASDAQ:BIIB) reported better-than-expected earnings for its fourth quarter on Wednesday.</p>\n<p>The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.</p>\n<p>Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.</p>\n<p>Biogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.</p>\n<p>Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.</p>\n<p>Biogen shares fell 4.3% to close at $133.43 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Biogen following earnings announcement.</p>\n<ul>\n<li>Canaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.</li>\n<li>Truist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.</li>\n<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.</li>\n</ul>\n<p><strong>Considering buying BIIB stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"569\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121.png 1135w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 3 Utilities Stocks That May Collapse In Q1</strong></li>\n</ul></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.benzinga.com/25/02/43693765/biogen-analysts-lower-their-forecasts-after-q4-results","article_id":"2511240528","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2511240528","pubTimestamp":1739455406,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"百健(Biogen)分析师在第四季度业绩公布后下调预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1},"content_text":"Biogen Inc (NASDAQ:BIIB) reported better-than-expected earnings for its fourth quarter on Wednesday.\nThe company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.\nMultiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.\nBiogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.\nRevenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.\nBiogen shares fell 4.3% to close at $133.43 on Wednesday.\nThese analysts made changes to their price targets on Biogen following earnings announcement.\n\nCanaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.\nTruist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.\nHC Wainwright & Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.\n\nConsidering buying BIIB stock? Here’s what analysts think: \n\nRead This Next: \n\nTop 3 Utilities Stocks That May Collapse In Q1","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}